Home › Prostate Cancer › Maryland
Prostate Cancer clinical trials in Maryland
65 studies for Prostate Cancer are looking for participants at sites in Maryland.
Cities in Maryland
Imaging Studies to Check the Local Response of Prostate Cancer to Radiation Therapy
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational study
Ages 18 to 120 · Men · Updated Oct 2, 2026 · NCT01834001IL-15 Superagonist With or Without Vaccine in Biochemically Recurrent Prostate Cancer After Previous Stereotactic Body Radiation Therapy
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 2
Ages 18 to 120 · Men · Updated Oct 2, 2026 · NCT07686380Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
- Maryland Proton Treatment Center, Baltimore
- University of Maryland/Greenebaum Cancer Center, Baltimore
- UM Upper Chesapeake Medical Center, Bel Air
- and 3 more
RecruitingPhase 3
Ages 18 and older · Men · Updated Oct 2, 2026 · NCT07200830Collection of Blood From Patients With Prostate Cancer
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational study
Ages 18 and older · Men · Updated Oct 2, 2026 · NCT00923221Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Mercy Medical Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- MedStar Franklin Square Medical Center/Weinberg Cancer Institute, Baltimore
- and 10 more
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Oct 2, 2026 · NCT05334069Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational study
Ages 3 and older · All sexes · Updated Oct 2, 2026 · NCT01441089A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Johns Hopkins University, Baltimore
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06172478Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- National Institutes of Health Clinical Center, Bethesda
- FMH James M Stockman Cancer Institute, Frederick
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT03866382Collection of Blood From Patients With Cancer
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational studyHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT00034216Precision-Based Genomics in Prostate Cancer
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational study
Ages 18 to 120 · Men · Updated Sep 28, 2026 · NCT04706663Prostate Cancer Risk Identification in a Multi-Ethnic Cohort: a Prospective US-based Multi-center Validation Study of Proclarix
- Chesapeake Urology Associates, Hanover
- Chesapeake Urology Associates, Towson
RecruitingObservational study
Ages 40 to 75 · Men · Updated Sep 28, 2026 · NCT07543757Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer
- University of Maryland, Greenebaum Comprehensive Cancer Center, Baltimore
RecruitingPhase 1
Ages 18 and older · Men · Updated Sep 25, 2026 · NCT06801236A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
- Baltimore Veterans Affairs Medical Center ( Site 0069), Baltimore
- Greenebaum Comprehensive Cancer Center ( Site 0049), Baltimore
- Chesapeake Urology ( Site 0009), Towson
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06136650Prospective Monitoring of Subjects With Biochemically Recurrent Prostate Cancer Using 18FDCFPyL
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational study
Ages 18 and older · Men · Updated Sep 22, 2026 · NCT05588128Care of the Prostate Cancer Patient and Prospective Procurement of Prostate Cancer Tissue
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational study
Ages 18 and older · Men · Updated Sep 22, 2026 · NCT02594202A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
- University of Maryland Greenebaum Cancer Center, Baltimore
- Johns Hopkins Hospital Sidney Kimmell Comprehensive Cancer Center, Baltimore
RecruitingPhase 3
Ages 18 and older · Men · Updated Sep 22, 2026 · NCT07213674A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
- Research Site, Towson
RecruitingPhase 3
Ages 18 and older · Men · Updated Sep 18, 2026 · NCT06952803A Phase II Study Evaluating T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine PDS01ADC in Localized High and Intermediate Risk Prostate Cancer Treated With Androgen Deprivation Therapy
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 2
Ages 18 and older · Men · Updated Sep 18, 2026 · NCT05361798Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 2
Ages 18 to 120 · Men · Updated Sep 17, 2026 · NCT05616650A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
- Greenebaum Comprehensive Cancer Center ( Site 0021), Baltimore
RecruitingPhase 3
Ages 18 and older · Men · Updated Sep 17, 2026 · NCT06925737PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore
RecruitingObservational study
Ages 18 and older · Men · Updated Sep 15, 2026 · NCT04995198A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec
- Chesapeake Urology Research Associates, Towson
RecruitingPhase 2
Ages 18 and older · Men · Updated Sep 15, 2026 · NCT07332000Sacral Neuromodulation for Male Overactive Bladder (MOAB)
- Anne Arundel Urology, Annapolis
Recruiting
Ages 18 and older · Men · Updated Sep 14, 2026 · NCT06511141Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
- Maryland Proton Treatment Center, Baltimore
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Veterans Administration Medical Center-Baltimore, Baltimore
- and 7 more
RecruitingPhase 3
Ages 18 and older · Men · Updated Sep 10, 2026 · NCT05946213Profiling of Radiological Factors in Treatment and Outcomes in Prostate Cancer
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational study
Ages 18 and older · Men · Updated Sep 8, 2026 · NCT03354416Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 2
Ages 18 to 120 · Men · Updated Sep 3, 2026 · NCT06096870Patient Navigation Program to Improve Clinical Trial Enrollment in Cancer Patients
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore
Recruiting
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT06138067Men at High Genetic Risk for Prostate Cancer
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational study
Ages 30 to 75 · Men · Updated Sep 3, 2026 · NCT03805919A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 1/2
Ages 18 to 110 · Men · Updated Sep 3, 2026 · NCT04633252The Vanguard Study: Testing a New Way to Screen for Cancer
- Walter Reed National Military Medical Center, Bethesda
RecruitingHealthy volunteers welcome
Ages 45 to 75 · All sexes · Updated Sep 2, 2026 · NCT06995898Multiparametric Magnetic Resonance Imaging of the Prostate to Assess Disease Progression and Genomics in Patients Undergoing Active Surveillance for Prostate Cancer
- National Institutes of Health Clinical Center, Bethesda
Recruiting
Ages 18 and older · Men · Updated Aug 27, 2026 · NCT04692675Transrectal Ultrasound Robot-Assisted Prostate Biopsy
- Johns Hopkins Hospital, Baltimore
Recruiting
Ages 45 to 75 · Men · Updated Aug 26, 2026 · NCT02871726Study of Oral MRT-2359 With Apalutamide in Prostate Cancer
- University of Maryland Greenebaum Cancer Center, Baltimore
RecruitingPhase 2
Ages 18 and older · Men · Updated Aug 24, 2026 · NCT07745361A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC
- Johns Hopkins Hospital, Baltimore
RecruitingPhase 1/2
Ages 18 and older · Men · Updated Aug 20, 2026 · NCT06785636Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
- Suburban Hospital, Bethesda
RecruitingPhase 3
Ages 18 and older · Men · Updated Aug 19, 2026 · NCT04423211FOG-001 in Locally Advanced or Metastatic Solid Tumors
- Johns Hopkins University, The Sidney Kimmel Comprehensive Cancer Center, Baltimore
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT05919264Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
- University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore
RecruitingPhase 1
Ages 18 to 100 · Men · Updated Aug 13, 2026 · NCT05519449Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer
- Johns Hopkins University, Baltimore
RecruitingObservational study
Ages 18 and older · Men · Updated Aug 12, 2026 · NCT04489719Surface Electrical Stimulation for Urinary Incontinence in Men Treated for Prostate Cancer
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 2
Ages 18 to 120 · Men · Updated Jul 24, 2026 · NCT06161506Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
- Christiana Care - Union Hospital, Elkton
RecruitingPhase 3
Ages 18 and older · Men · Updated Jul 14, 2026 · NCT06592924From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.